7,640.50

+26.50

+0.35%

52,019.00

+101.00

+0.19%

28,744.50

+210.50

+0.74%

Russell 2000 Futures

2,834.00

+12.70

+0.45%

4.9290

-0.0600

-1.20%

19.08

-0.34

-1.75%

3,904.00

+5.10

+0.13%

78,158.83

+48.59

+0.06%

Crude Oil Dec 26

100.28

-3.84

-3.69%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

WuXi AppTec Co., Ltd. (2359.HK)

180.000 -5.400 (-2.91%)

At close: 4:08:13 PM GMT+8

Loading Chart for 2359.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated

How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated

Peptide Manufacturing Trends: How Oral Dosing Raises API Demand

Peptide Manufacturing Trends: How Oral Dosing Raises API Demand

WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions

Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions

Oligonucleotide Drug Delivery Is Moving Beyond the Liver

Oligonucleotide Drug Delivery Is Moving Beyond the Liver

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year

Integrated Development Helps Targeted Protein Degraders Reach the Clinic

Integrated Development Helps Targeted Protein Degraders Reach the Clinic

Mobilize your Website

View Site in Mobile | Classic

Share by: